CD40 and posterior cortical atrophy: A phase I clinical trial also showed that CD40 activation enhanced anti-tumor immunity in patients with castration-resistant PCa [24], further validating A3C’s tumor-suppressive role and its potential as a target for CD40-related immunotherapy.